Sumitomo Dainippon Pharma

Jun. 09, 2021 (PDF/163KB)Licensing

Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound "NC-2800"
Jun. 03, 2021 (PDF/74KB)Corporate

Comments Regarding Media Article on Our Company
May 27, 2021 (PDF/172KB)Products

Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 24, 2021 (PDF/40KB)R&D

Myovant Sciences Receives Positive CHMP Opinion for RYEQO (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
May 18, 2021Finances

Posted Video of Investors Meeting Presentation for FY2020 (Year ended March 31, 2021) and Revision of Mid-term Business Plan 2022 [Webcast]

Other Notices

May 26, 2021Corporate

Posted Notice of Convocation of the 201th Annual Shareholders' Meeting
Mar. 25, 2021Corporate (PDF/129KB)

Sumitomo Dainippon Pharma Announces the Launch of Website Dedicated to Frontier Business
Nov. 20, 2020Others

Posted Factbook 2020 ver.2

IR Library

Company Introduction Movie

Continuing to challenge ourselves to support a healthy future for people
Research and Development

Aiming to create innovative pharmaceutical products
Frontier Business Website

Thinking BEYOND medication
CSR

Targeting sustainable growth
Overseas Local Subsidiaries

Leading our global expansion